Interestingly, we observed that treatment with TRIB2-shRNA decreased TRIB2 protein level and proportionately reduced the viability of enzalutamide-resistant cells, suggesting that TRIB2 plays a critical role in the enzalutamide resistance mechanism in prostate cancer cells (Fig. 2). This evidence concerns the gene TRIB2 and prostate cancer.